Skip to main content

Current application of cannabidiol (CBD) in the management and treatment of neurological disorders


Cannabidiol (CBD), which is nonintoxicating pharmacologically relevant constituents of Cannabis, demonstrates several beneficial effects. It has been found to have antioxidative, anti-inflammatory, and neuroprotective effects. As the medicinal use of CBD is gaining popularity for treatment of various disorders, the recent flare-up of largely unproven and unregulated cannabis-based preparations on medical therapeutics may have its greatest impact in the field of neurology. Currently, as lot of clinical trials are underway, CBD demonstrates remarkable potential to become a supplemental therapy in various neurological conditions. It has shown promise in the treatment of neurological disorders such as anxiety, chronic pain, trigeminal neuralgia, epilepsy, and essential tremors as well as psychiatric disorders. While recent FDA-approved prescription drugs have demonstrated safety, efficacy, and consistency enough for regulatory approval in spasticity in multiple sclerosis (MS) and in Dravet and Lennox-Gastaut Syndromes (LGS), many therapeutic challenges still remain. In the current review, the authors have shed light on the application of CBD in the management and treatment of various neurological disorders.

This is a preview of subscription content, access via your institution.


  1. 1.

    Volkow ND, Compton WM, Weiss SR (2014) Adverse health effects of marijuana use. N Engl J Med 371(9):878–879.

    Article  Google Scholar 

  2. 2.

    Volkow ND, Swanson JM, Evins AE, DeLisi LE, Meier MH, Gonzalez R, Bloomfield MA, Curran HV, Baler R (2016) Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiatry 73(3):292–297.

    Article  PubMed  Google Scholar 

  3. 3.

    Jamil M, Zafar A, Adeel Faizi S, Zawar I (2016) Stroke from vasospasm due to marijuana use: can cannabis synergistically with other medications trigger cerebral vasospasm? Case Rep Neurol Med 2016:5313795–5313794.

    Article  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Bergamaschi MM, Queiroz RH, Zuardi AW, Crippa JA (2011) Safety and side effects of cannabidiol, a cannabis sativa constituent. Curr Drug Saf 6(4):237–249.

    CAS  Article  PubMed  Google Scholar 

  5. 5.

    Grotenhermen F, Müller-Vahl K (2016) Cannabis und cannabinoide in der medizin: fakten und ausblick. Suchttherapie 17(02):71–76.

    Article  Google Scholar 

  6. 6.

    Hampson AJ, Grimaldi M, Axelrod J, Wink D (1998) Cannabidiol and (−)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A 95(14):8268–8273.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  7. 7.

    Oláh A, Tóth BI, Borbíró I, Sugawara K, Szöllõsi AG, Czifra G, Pál B, Ambrus L, Kloepper J, Camera E, Ludovici M, Picardo M, Voets T, Zouboulis CC, Paus R, Bíró T (2014) Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. J Clin Investig 124(9):3713–3724.

    Article  PubMed  Google Scholar 

  8. 8.

    Mikuriya TH (1969) Marijuana in medicine: past, present and future. Calif Med 110(1):34–40

    CAS  PubMed  PubMed Central  Google Scholar 

  9. 9.

    Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R, Cuomo G, Abate M, Faggiana G, Proto MC, Fiore D, Laezza C, Bifulco M (2017) Cannabidiol: state of the art and new challenges for therapeutic applications. Pharmacol Ther 175:133–150.

    CAS  Article  PubMed  Google Scholar 

  10. 10.

    Mechoulam R, Shvo Y (1963) Hashish—I: the structure of cannabidiol. Tetrahedron 19(12):2073–2078

    CAS  Article  Google Scholar 

  11. 11.

    Scuderi C, Filippis DD, Iuvone T, Blasio A, Steardo A, Esposito G (2009) Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders. Phytother Res 23(5):597–602.

    CAS  Article  PubMed  Google Scholar 

  12. 12.

    Ramer R, Heinemann K, Merkord J, Rohde H, Salamon A, Linnebacher M, Hinz B (2013) COX-2 and PPAR-gamma confer cannabidiol-induced apoptosis of human lung cancer cells. Mol Cancer Ther 12(1):69–82.

    CAS  Article  PubMed  Google Scholar 

  13. 13.

    Pertwee RG (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74(2):129–180

    CAS  Article  Google Scholar 

  14. 14.

    Lunn CA, Reich EP, Bober L (2006) Targeting the CB2 receptor for immune modulation. Expert Opin Ther Targets 10(5):653–663.

    CAS  Article  PubMed  Google Scholar 

  15. 15.

    Veronesi B, Oortgiesen M (2006) The TRPV1 receptor: target of toxicants and therapeutics. Toxicol Sci 89(1):1–3.

    CAS  Article  PubMed  Google Scholar 

  16. 16.

    Pazos MR, Mohammed N, Lafuente H, Santos M, Martinez-Pinilla E, Moreno E, Valdizan E, Romero J, Pazos A, Franco R, Hillard CJ, Alvarez FJ, Martinez-Orgado J (2013) Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: role of 5HT(1A) and CB2 receptors. Neuropharmacology 71:282–291.

    CAS  Article  PubMed  Google Scholar 

  17. 17.

    Rock EM, Limebeer CL, Mechoulam R, Piomelli D, Parker LA (2008) The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat. Psychopharmacology 196(3):389–395.

    CAS  Article  PubMed  Google Scholar 

  18. 18.

    Soares Vde P, Campos AC, Bortoli VC, Zangrossi H Jr, Guimaraes FS, Zuardi AW (2010) Intra-dorsal periaqueductal gray administration of cannabidiol blocks panic-like response by activating 5-HT1A receptors. Behav Brain Res 213(2):225–229.

    CAS  Article  PubMed  Google Scholar 

  19. 19.

    Chen JW, Borgelt LM, Blackmer AB (2019) Cannabidiol: a new hope for patients with Dravet or Lennox-Gastaut syndromes. Ann Pharmacother 53(6):603–611.

    CAS  Article  PubMed  Google Scholar 

  20. 20.

    Samara E, Bialer M, Harvey DJ (1990) Pharmacokinetics of urinary metabolites of cannabidiol in the dog. Biopharm Drug Dispos 11(9):785–795

    CAS  Article  Google Scholar 

  21. 21.

    Wang T, Collet JP, Shapiro S, Ware MA (2008) Adverse effects of medical cannabinoids: a systematic review. CMAJ 178(13):1669–1678.

    Article  PubMed  PubMed Central  Google Scholar 

  22. 22.

    Mead A (2016) The legal and regulatory status of cannabidiol (CBD). Planta Med 82(05).

  23. 23.

    Mead A (2017) The legal status of cannabis (marijuana) and cannabidiol (CBD) under U.S. law. Epilepsy Behav 70(Pt B):288–291.

    Article  PubMed  Google Scholar 

  24. 24.

    Urits I, Borchart M, Hasegawa M, Kochanski J, Orhurhu V, Viswanath O (2019) An update of current cannabis-based pharmaceuticals in pain medicine. Pain Ther 8(1):41–51.

    Article  PubMed  PubMed Central  Google Scholar 

  25. 25.

    Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D (2007) Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain 133(1–3):210–220.

    CAS  Article  PubMed  Google Scholar 

  26. 26.

    CADTH rapid response reports (2016) Cannabinoid buccal spray for chronic non-cancer or neuropathic pain: a review of clinical effectiveness, safety, and guidelines. In: CADTH Rapid Response Reports. Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)

    Google Scholar 

  27. 27.

    Blake DR, Robson P, Ho M, Jubb RW, McCabe CS (2006) Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford) 45(1):50–52.

    CAS  Article  Google Scholar 

  28. 28.

    Arjmand S, Vaziri Z, Behzadi M, Abbassian H, Stephens GJ, Shabani M (2015) Cannabinoids and tremor induced by motor-related disorders: friend or foe? Neurotherapeutics 12(4):778–787.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  29. 29.

    Ibeas Bih C, Chen T, Nunn AV, Bazelot M, Dallas M, Whalley BJ (2015) Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics 12(4):699–730.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  30. 30.

    Abbassian H, Whalley BJ, Sheibani V, Shabani M (2016) Cannabinoid type 1 receptor antagonism ameliorates harmaline-induced essential tremor in rat. Br J Pharmacol 173(22):3196–3207.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  31. 31.

    Kolasiewicz W, Kuter K, Wardas J, Ossowska K (2009) Role of the metabotropic glutamate receptor subtype 1 in the harmaline-induced tremor in rats. J Neural Transm (Vienna) 116(9):1059–1063.

    CAS  Article  Google Scholar 

  32. 32.

    Handforth A (2012) Harmaline tremor: underlying mechanisms in a potential animal model of essential tremor. Tremor Other Hyperkinet Mov (N Y) 2.

  33. 33.

    Iuvone T, Esposito G, De Filippis D, Scuderi C, Steardo L (2009) Cannabidiol: a promising drug for neurodegenerative disorders? CNS Neurosci Ther 15(1):65–75.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  34. 34.

    Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernandez-Ruiz J (2005) Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol Dis 19(1–2):96–107.

    CAS  Article  PubMed  Google Scholar 

  35. 35.

    Devinsky O, Marsh E, Friedman D (2016) Cannabidiol in patients with treatment-resistant epilepsy - Authors' reply. Lancet Neurol 15(6):545–546.

    Article  PubMed  Google Scholar 

  36. 36.

    Laurie K Mischley N (2019) Cannabis and Parkinson's disease tremor: a natural history study.

  37. 37.

    Blessing EM, Steenkamp MM, Manzanares J, Marmar CR (2015) Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics 12(4):825–836.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  38. 38.

    Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG (1982) Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology 76(3):245–250

    CAS  Article  Google Scholar 

  39. 39.

    Zuardi AW, Cosme RA, Graeff FG, Guimaraes FS (1993) Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol 7(1 Suppl):82–88.

    CAS  Article  PubMed  Google Scholar 

  40. 40.

    McDonough P, McKenna JP, McCreary C, Downer EJ (2014) Neuropathic orofacial pain: cannabinoids as a therapeutic avenue. Int J Biochem Cell Biol 55:72–78.

    CAS  Article  PubMed  Google Scholar 

  41. 41.

    Chagas MH, Eckeli AL, Zuardi AW, Pena-Pereira MA, Sobreira-Neto MA, Sobreira ET, Camilo MR, Bergamaschi MM, Schenck CH, Hallak JE, Tumas V, Crippa JA (2014) Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series. J Clin Pharm Ther 39(5):564–566.

    CAS  Article  PubMed  Google Scholar 

  42. 42.

    Consroe P, Musty R, Rein J, Tillery W, Pertwee R (1997) The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 38(1):44–48.

    CAS  Article  PubMed  Google Scholar 

  43. 43.

    Elliott J, McCoy B, Clifford T, Potter BK, Skidmore B, Wells GA, Coyle D (2019) Cost-effectiveness of cannabinoids for pediatric drug-resistant epilepsy: protocol for a systematic review of economic evaluations. Syst Rev 8(1):75.

    Article  PubMed  PubMed Central  Google Scholar 

  44. 44.

    Liang YC, Huang CC, Hsu KS (2007) The synthetic cannabinoids attenuate allodynia and hyperalgesia in a rat model of trigeminal neuropathic pain. Neuropharmacology 53(1):169–177.

    CAS  Article  PubMed  Google Scholar 

  45. 45.

    Harold Merskey D (1994) Classification of chronic pain: description of chronic pain syndromes and definitions of pain terms, 2nd edn. IASP PRESS, Seattle

    Google Scholar 

  46. 46.

    Mondello E, Quattrone D, Cardia L, Bova G, Mallamace R, Barbagallo AA, Mondello C, Mannucci C, Di Pietro M, Arcoraci V, Calapai G (2018) Cannabinoids and spinal cord stimulation for the treatment of failed back surgery syndrome refractory pain. J Pain Res 11:1761–1767.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  47. 47.

    Peul WC, van Houwelingen HC, van den Hout WB, Brand R, Eekhof JA, Tans JT, Thomeer RT, Koes BW, Leiden-The Hague Spine Intervention Prognostic Study G (2007) Surgery versus prolonged conservative treatment for sciatica. N Engl J Med 356(22):2245–2256.

    CAS  Article  PubMed  Google Scholar 

  48. 48.

    Compston A, Coles A (2002) Multiple sclerosis. Lancet 359(9313):1221–1231.

    Article  PubMed  Google Scholar 

  49. 49.

    Perras C (2005) Sativex for the management of multiple sclerosis symptoms. Issues Emerg Health Technol 72:1–4

    Google Scholar 

  50. 50.

    Koppel BS, Brust JC, Fife T, Bronstein J, Youssof S, Gronseth G, Gloss D (2014) Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 82(17):1556–1563.

    Article  PubMed  PubMed Central  Google Scholar 

  51. 51.

    Consroe P, Kennedy K, Schram K (1991) Assay of plasma cannabidiol by capillary gas chromatography/ion trap mass spectroscopy following high-dose repeated daily oral administration in humans. Pharmacol Biochem Behav 40(3):517–522

    CAS  Article  Google Scholar 

  52. 52.

    Hussain SA, Zhou R, Jacobson C, Weng J, Cheng E, Lay J, Hung P, Lerner JT, Sankar R (2015) Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: a potential role for infantile spasms and Lennox-Gastaut syndrome. Epilepsy Behav 47:138–141.

    Article  PubMed  Google Scholar 

  53. 53.

    Kurz R, Blaas K (2010) Use of dronabinol (delta-9-THC) in autism: a prospective single-case-study with an early infantile autistic child. Cannabinoids 5(4):4–6

    Google Scholar 

  54. 54.

    Fernandez-Lopez D, Lizasoain I, Moro MA, Martinez-Orgado J (2013) Cannabinoids: well-suited candidates for the treatment of perinatal brain injury. Brain Sci 3(3):1043–1059.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  55. 55.

    Fisher T, Golan H, Schiby G, PriChen S, Smoum R, Moshe I, Peshes-Yaloz N, Castiel A, Waldman D, Gallily R, Mechoulam R, Toren A (2016) In vitro and in vivo efficacy of non-psychoactive cannabidiol in neuroblastoma. Curr Oncol 23(2):S15–S22.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  56. 56.

    Burns HD, Van Laere K, Sanabria-Bohorquez S, Hamill TG, Bormans G, Eng WS, Gibson R, Ryan C, Connolly B, Patel S, Krause S, Vanko A, Van Hecken A, Dupont P, De Lepeleire I, Rothenberg P, Stoch SA, Cote J, Hagmann WK, Jewell JP, Lin LS, Liu P, Goulet MT, Gottesdiener K, Wagner JA, de Hoon J, Mortelmans L, Fong TM, Hargreaves RJ (2007) [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc Natl Acad Sci U S A 104(23):9800–9805.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  57. 57.

    Hayatbakhsh MR, Najman JM, Jamrozik K, Mamun AA, Alati R, Bor W (2007) Cannabis and anxiety and depression in young adults: a large prospective study. J Am Acad Child Adolesc Psychiatry 46(3):408–417.

    Article  PubMed  Google Scholar 

  58. 58.

    Fontes MA, Bolla KI, Cunha PJ, Almeida PP, Jungerman F, Laranjeira RR, Bressan RA, Lacerda AL (2011) Cannabis use before age 15 and subsequent executive functioning. Br J Psychiatry 198(6):442–447.

    Article  PubMed  PubMed Central  Google Scholar 

  59. 59.

    Batalla A, Janssen H, Gangadin SS, Bossong MG (2019) The potential of Cannabidiol as a treatment for psychosis and addiction: who benefits Most? A systematic review. J Clin Med 8(7).

  60. 60.

    Zuardi AW, Crippa JA, Hallak JE, Bhattacharyya S, Atakan Z, Martin-Santos R, McGuire PK, Guimaraes FS (2012) A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. Curr Pharm Des 18(32):5131–5140.

    CAS  Article  PubMed  Google Scholar 

  61. 61.

    Walther S, Halpern M (2010) Cannabinoids and dementia: a review of clinical and preclinical data. Pharmaceuticals 3(8):2689–2708.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Syed A. Quadri.

Ethics declarations

Conflict of interest

The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

Ethical approval and informed consent

This is a review which did not include any human research subject participation. Therefore, no informed consent or ethical approval was required for this review.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Fiani, B., Sarhadi, K.J., Soula, M. et al. Current application of cannabidiol (CBD) in the management and treatment of neurological disorders. Neurol Sci 41, 3085–3098 (2020).

Download citation


  • Cannabidiol
  • Efficacy
  • Ethicality
  • Neurologic disorders